REG - Scancell Hlds - Issue of share options
20/02/2025 07:15
For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250220:nRST7667Xa&default-theme=true
RNS Number : 7667X Scancell Holdings Plc 20 February 2025
Scancell Holdings plc
("Scancell" or the "Company")
Issue of share options
Scancell Holdings plc (AIM: SCLP), a clinical-stage biopharmaceutical company
developing novel immunotherapies for cancer, announces that on 19 February
2025, share options to acquire ordinary shares of 0.1 pence each in the
capital of the Company (the "Options") were granted to Phil L'Huillier, CEO
and Executive Director, Lindy Durrant, CSO and Executive Director and Sath
Nirmalananthan, CFO and Executive Director (the "Executive Directors").
The Options have been granted as follows:
Director Existing options over Ordinary Shares Number of Options granted Total options held following grant % of current issued share capital
Phil L'Huillier 0 31,103,440 31,103,440 3.00%
Lindy Durrant 22,850,000 5,183,907 28,033,907 2.70%
Sath Nirmalananthan 1,000,000 1,000,000 2,000,000 0.19%
The Options have been granted pursuant to the Company's long term incentive
plan, have an exercise price of 11.7 pence each, the 3 month volume
weighted average price on the grant date, and will vest over three years in
three equal tranches from 19 February 2025 with no vesting criteria other than
to remain in employment. Any unexercised Options which are being granted per
the above will expire at 6pm on 19 February 2035.
The Board of Scancell approved the issuance of the Options to incentivise and
retain directors and staff of the Company. The Board considered both
historical practices and on-going funding requirements in this regard.
Related Party Transaction
The issue of Options to the Executive Directors are deemed to be a related
party transaction pursuant to AIM Rule 13 of the AIM Rules for Companies. The
Company's directors who are independent of the related party transaction,
being all the directors other than the Executive Directors, consider, having
consulted with the Company's Nominated Adviser, Panmure Liberum Limited, that
the terms of the related party transactions are fair and reasonable insofar as
the shareholders of the Company are concerned.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name Phil L'Huillier
2 Reason for the notification
a) Position/status Chief Executive Officer and PDMR
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Scancell Holdings plc
b) LEI 2138008RXEG856SNP666
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Options to acquire ordinary shares
b) Identification Code GB00B63D3314
c) Nature of the transaction Grant of options to acquire ordinary shares
d) Price(s) and volume(s) 31,103,440 share options
11.7 pence per share option
e) Aggregated information
- Aggregated volume N/A (single transaction)
- Price
f) Date of the transaction 19 February 2025
g) Place of the transaction Outside a trading venue
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name Lindy Durrant
2 Reason for the notification
a) Position/status Chief Scientific Officer and PDMR
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Scancell Holdings plc
b) LEI 2138008RXEG856SNP666
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Options to acquire ordinary shares
b) Identification Code GB00B63D3314
c) Nature of the transaction Grant of options to acquire ordinary shares
d) Price(s) and volume(s) 5,183,907 share options
11.7 pence per share option
e) Aggregated information
- Aggregated volume N/A (single transaction)
- Price
f) Date of the transaction 19 February 2025
g) Place of the transaction Outside a trading venue
1 Details of the person discharging managerial responsibilities/person closely
associated
a) Name Sath Nirmalananthan
2 Reason for the notification
a) Position/status Chief Financial Officer and PDMR
b) Initial notification/Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Scancell Holdings plc
b) LEI 2138008RXEG856SNP666
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Options to acquire ordinary shares
b) Identification Code GB00B63D3314
c) Nature of the transaction Grant of options to acquire ordinary shares
d) Price(s) and volume(s) 1,000,000 share options
11.7 pence per share option
e) Aggregated information
- Aggregated volume N/A (single transaction)
- Price
f) Date of the transaction 19 February 2025
g) Place of the transaction Outside a trading venue
-ENDS-
For further information, please contact:
Scancell Holdings plc
+44 (0) 20 3709 5700
Phil L'Huillier, CEO
Sath Nirmalananthan, CFO
Professor Lindy Durrant, CSO
Dr Jean-Michel Cosséry, Non-Executive Chairman
Panmure Liberum Limited (Nominated Advisor and Joint Broker)
+44 (0) 20 7886 2500
Emma Earl/ Will Goode/ Mark Rogers (Corporate Finance)
Rupert Dearden (Corporate Broking)
WG Partners LLP (Joint Broker)
+44 (0) 20 3705 9330
David Wilson/ Claes Spang/ Satheesh Nadarajah/ Erland Sternby
ICR Healthcare
+44 (0) 20 37095700
Mary-Jane Elliott/ Angela Gray/ Stephanie Cuthbert
scancell@icrhealthcare.com
(mailto:scancell@icrhealthcare.com)
About Scancell
Scancell is a clinical stage biopharmaceutical company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer. The Company is building a pipeline of innovative products by utilising
its four technology platforms: Moditope® and ImmunoBody® for vaccines and
GlyMab® and AvidiMab® for antibodies. Adaptive immune responses include
antibodies and T cells (CD4 and CD8), both of which can recognise damaged or
infected cells. In order to destroy such cancerous or infected cells, Scancell
uses either vaccines to induce immune responses or monoclonal antibodies
(mAbs) to redirect immune cells or drugs. The Company's unique approach is
that its innovative products target modifications of proteins and lipids. For
the vaccines (Moditope® and ImmunoBody® ) this includes citrullination and
homocitrullination of proteins, whereas its mAb portfolio targets glycans or
sugars that are added onto proteins and / or lipids (GlyMab® ) or enhances
the potency of antibodies and their ability to directly kill tumour cells
(AvidiMab® ).
For further information about Scancell, please
visit: https://www.scancell.co.uk/ (https://www.scancell.co.uk/)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHBRGDDGUBDGUCRecent news on Scancell Holdings
See all newsREG - Scancell Hlds - Partnership with NHS Cancer Vaccine Launch Pad
AnnouncementREG - Scancell Hlds - Scancell to present at 2025 AACR Annual Meeting
AnnouncementREG - Scancell Hlds - Issue of share options
AnnouncementREG - Scancell Hlds - Scancell presenting at AACR IO conference
AnnouncementREG - Scancell Hlds - Interim Results
Announcement